A new approach for the pleiotropic effect of metformin use in type 2 diabetes mellitus

Abstract

Metformin is the first choice for type 2 diabetes mellitus (T2DM) treatment in the guidelines and is used in combination with many drugs. Growth arrest-specific protein 6 (Gas6)/Axl signaling plays a role in many metabolic disorders. This study aims to investigate the effects of metformin and metformin-insulin combination used in patients with T2DM on Gas6, Axl, and soluble Axl (sAxl) levels.

Keywords

• axl
• gas6
• metformin
• saxl
• tip 2 diabetes mellitus